乳腺癌多发性骨转移的预后和153Sm-EDTMP治疗结果

目的：分析乳腺癌多发性骨转移的预后和＾１５３Ｓｍ－乙二胺四甲基膦酸（ＥＤＴＭＰ）治疗效果。方法：回顾分析１９９２年至１９９８年１３１例接受了＾１５３Ｓｍ－ＥＤＴＭＰ治疗的乳腺癌多发性骨转移病人。所有病人经病理或细胞学证实为乳膛癌。骨转移灶经骨显像、Ｘ光片、ＣＴ和／或ＭＲＩ诊断证实。结果：全组病人总的５年生存率为５９％，骨转移后５年生存率和中位生存期分别为１８．５％和１５个月。转移局限于骨的病人比骨

Prognosis of breast cancer patients with multiple bone metastases and therapeutic effect of 153samarium-EDTMP

Objective: To analyze the prognosis of breast cancer patients with multiple bone metastases and evaluate therapeutic effect of 153Sm EDTMP to the patient Methods: Between 1992 and 1998, 131 breast cancer patients with painful multiple bone metastasis treated with 153Sm EDTMP were retrospectively reviewed All patients were histologically confirmed as breast cancer Bone metastasis was further diagnosed with ECT, X ray, CT and/or MRI Results: The overall 5 year survival rate for all patients was 59% The post bone metastasis 5 year survival rate was 18 5%and median survival time was 15 months Patients with metastasis disease confined to the skeleton had a longer survival as compared to those with both bone and local regional or other distant metastases (P<0 001) The corresponding post bone metastasis 5 year survival was 26 3%and 13 7%, respectively All patients with painful multiple skeletal metastases treated with 153Sm EDTMP got positive response of 81 7 %,(complete response 34 4%and partial response 47 3%), while twenty four (18 3%) patients showed no response The efficacy of 153Sm EDTMP was associated with prognosis The post bone metastasis survival for patients with complete response was significantly better than those with partial or no response The corresponding post bone metastasis 5 year survival was 32 8%,10 4%, and 11 4%, respectively (P<0 001) Conclusion: Breast cancerpatient with skeletal metastases is an indolent clinical course 153Sm EDTMP is an effective agent for these patients with painful multiple bone metastases and its efficiency is an important prognostic factor